RN7SL163P

Across TCGA pan-cancer cohorts, RN7SL163P RNA differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of RN7SL163P’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where RN7SL163P RNA is more highly expressed in tumor relative to normal tissue. In most cancer types RN7SL163P is over-expressed in tumor, although a few such as LUAD show the opposite, repressed pattern.

LIHC, COAD, and ESCA are the cancer types where RN7SL163P tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RN7SL163P RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	All	All	+0.094	.001	4	view →
COAD	All	All	+0.152	.009	3	view →
ESCA	All	II,III,IV	+0.440	<.001	2	view →
CHOL	All	II,III,IV	+0.335	<.001	2	view →
LUAD	All	II,III,IV	−0.067	.040	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

RN7SL163P–LIHC

Open the LIHC breakdown →